Shownotes
Few oncologists know neuroendocrine tumors from both sides of the exam table: first as a patient diagnosed during training, and now as the doctor treating them. This physician brings both perspectives to one pressing question: when a tumor progresses on a somatostatin analog, what comes next? On this episode of BackTable Tumor Board, Dr. Aman Chauhan, a medical oncologist at UCSF, interviews Dr. Mark Lewis, director of gastrointestinal oncology at Intermountain Health in Salt Lake City, about treatment strategies for advanced neuroendocrine tumors beyond first-line therapy. They start with…

